

Helsinki, 5 June 2020

**Addressees**

Registrants of JS\_EC234-196-6 listed in the last Appendix of this decision

**Date of submission for the jointly submitted dossier subject of a decision**

19/04/2013

**Registered substance subject to this decision, hereafter 'the Substance'**

Substance name: N,N'-dimethyldiphenylthiuram disulphide

EC number: 234-196-6

CAS number: 10591-84-1

**Decision number:** [Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXX-XX-XX/F)]**DECISION ON A TESTING PROPOSAL**

Based on Article 40 of Regulation (EC) No 1907/2006 (REACH), ECHA requests that you submit the information listed below by the deadline of **14 March 2022**.

Requested information must be generated using the Substance unless otherwise specified.

**A. Requirements applicable to all the Registrants subject to Annex IX of REACH**

1. Sub-chronic toxicity study (90-day), oral route (Annex IX, Section 8.6.2.; test method OECD TG 408) in rats;
2. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method OECD TG 414) in a first species (rat or rabbit), oral route.

**Conditions to comply with the requests**

Each addressee of this decision is bound by the requests for information corresponding to the REACH Annexes applicable to their own registered tonnage of the Substance at the time of evaluation of the jointly submitted dossier. To identify your legal obligations you have to comply with the requirements of Annexes VII to IX of REACH, if you have registered a substance at 100-1000 tpa.

Registrants are only required to share the costs of information they are required to submit to fulfil the information requirements for their registration.

The Appendix entitled Observations and technical guidance addresses the generic approach for the selection and reporting of the test material used to perform the required studies and provides generic recommendations and references to ECHA guidance and other reference documents.

You must submit the information requested in this decision by the deadline indicated above in an updated registration dossier and also update the chemical safety report, where relevant,

including any changes to classification and labelling, based on the newly generated information.

**Appeal**

This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to <http://echa.europa.eu/regulations/appeals> for further information.

**Failure to comply**

If you do not comply with the information required by this decision by the deadline indicated above, ECHA will notify the enforcement authorities of your Member State.

Approved<sup>1</sup> under the authority of Christel Schillinger-Musset, Director of Hazard Assessment

---

<sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

**Appendix A: Reasons for the requirements applicable to all the Registrants subject to Annex IX of REACH**

This decision is based on the examination of the testing proposals you submitted.

**1. Sub-chronic toxicity study (90-day), oral route (Annex IX, Section 8.6.2.)**

A sub-chronic toxicity study (90 day) is a standard information requirement in Annex IX, Section 8.6.2. to REACH.

You have submitted a testing proposal for a sub-chronic toxicity study (90 day) in rats by the oral route according to OECD TG 408 with the Substance.

ECHA notes that you provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

You proposed testing by the oral route, in rats. ECHA agrees with your proposal. According to OECD TG 408, the rat is the preferred species and the most appropriate route of administration is the oral route<sup>2</sup> because although the Substance is reported to occur as a dust with a significant proportion (>1% on weight basis) of particles of low water solubility and inhalable size (1.82% < 100 µm, MMAD < 50 µm), the available oral study indicates a concern for systemic toxicity, including haemolytic anaemia and histopathological changes in the spleen, that requires further information on repeated dose toxicity by the oral route.

Under Article 40(3)(a) of REACH, you are requested to carry out the proposed test with the Substance, including sperm parameters and a recovery group.

**2. Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.) in a first species**

A pre-natal developmental toxicity (PNDT) study (OECD TG 414) in one species is a standard information requirement under Annex IX, Section 8.7.2. to REACH.

You have submitted a testing proposal for a PNDT study according to OECD TG 414 with the Substance in rat by the oral route.

You provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.

You proposed testing with the rat as a first species and by the oral route. ECHA agrees with your proposal. You may select between the rat and the rabbit because both are preferred species under the OECD TG 414. The oral route is the most appropriate route of administration to investigate reproductive toxicity.

Under Article 40(3)(a) of REACH, you are requested to carry out the proposed test with the Substance.

---

<sup>2</sup> ECHA Guidance R.7a, Section R.7.5.4.3

## **Appendix B: Procedural history**

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 20 June 2019.

ECHA held a third party consultation for the testing proposals from 16 August 2019 until 30 September 2019. ECHA did not receive information from third parties.

For the purpose of the decision-making, this decision does not take into account any updates of registration dossiers after the date on which you were notified the draft decision according to Article 50(1) of REACH.

The decision making followed the procedure of Articles 50 and 51 of the REACH Regulation, as described below:

ECHA notified you of the draft decision and invited you to provide comments of the notification.

ECHA did not receive any comments within the notification period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

## Appendix C: Observations and technical guidance

1. This testing proposal examination decision does not prevent ECHA from initiating compliance checks at a later stage on the registrations present.

2. Failure to comply with the requests in this decision, or to otherwise fulfil the information requirements with a valid and documented adaptation, will result in a notification to the enforcement authorities of your Member State(s).

3. Test guidelines, GLP requirements and reporting

Under Article 13(3) of REACH, all new data generated as a result of this decision needs to be conducted according to the test methods laid down in a European Commission Regulation or according to international test methods recognised by the Commission or ECHA as being appropriate.

Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

Under Article 10 (a) (vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide: 'How to report robust study summaries'<sup>3</sup>.

4. Test material

### *Selection of the test material(s)*

The registrants of the Substance are responsible for agreeing on the composition of the test material to be selected for carrying out the tests required by the present decision. The test material selected must be relevant for all the registrants of the Substance, i.e. it takes into account the variation in compositions reported by all members of the joint submission. The composition of the test material(s) must fall within the boundary composition(s) of the Substance.

While selecting the test material you must take into account the impact of each constituent/impurity is known to have or could have on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected test material must contain that constituent/impurity.

### *Technical reporting of the test material*

The composition of the selected test material must be reported in the respective endpoint study record, under the Test material section. The composition must include all constituents of the test material and their concentration values. Without such detailed reporting, ECHA may not be able to confirm that the test material is relevant for the Substance and to all the registrants of the Substance.

Technical instructions are available in the manual "How to prepare registration and PPORD dossiers"<sup>4</sup>.

<sup>3</sup> <https://echa.europa.eu/practical-guides>

<sup>4</sup> <https://echa.europa.eu/manuals>

5. List of references of the ECHA Guidance and other guidance/ reference documents<sup>5</sup>

QSARs, read-across and grouping

Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 in this decision.

ECHA Read-across assessment framework (RAAF, March 2017)<sup>6</sup>

Toxicology

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Environmental toxicology and fate

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

PBT assessment

Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

OECD Guidance documents

Guidance Document on aqueous-phase aquatic toxicity testing of difficult test chemicals – No 23, referred to as OECD GD 23.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

---

<sup>5</sup> <https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>

<sup>6</sup> <https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across>

**Appendix D: List of the registrants to which the decision is addressed and the corresponding information requirements applicable to them**

<b>Registrant Name</b>	<b>Registration number</b>	<b>(Highest) Data requirements to be fulfilled</b>
[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]

Note: where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas the decision is sent to the actual registrant.